- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05153395
Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation
February 21, 2024 updated by: Jacqueline K Limberg, PhD, University of Missouri-Columbia
Novel Treatment for Brain Insulin Resistance and Hypoperfusion
The purpose of this project is to examine the impact of increases in brain insulin on sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
65
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jacqueline K Limberg, Ph.D.
- Phone Number: 5738822544
- Email: limbergj@missouri.edu
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65211
- Recruiting
- University of Missouri
-
Contact:
- Jacqueline K Limberg
- Phone Number: 573-882-2544
- Email: limbergj@missouri.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- healthy adult men and women;
- 18-45 years of age;
- BMI >18 kg/m2;
- non-pregnant/non-breastfeeding;
- non-nicotine users;
Exclusion Criteria:
- taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic
Self-reported history of:
- hepatic, renal, pulmonary, cardiovascular, or neurological disease;
- stroke or neurovascular disease;
- bleeding/clotting disorders;
- sleep apnea or other sleep disorders;
- diabetes;
- smoking;
- history of alcoholism or substance abuse;
- hypertension;
- respiratory disease;
- active cancer;
- autoimmune disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Insulin (Doppler)
Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.
|
Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
Participants will be asked to repeatedly open and close their eyes.
With eyes open, participants will focus on a visual image.
This will be done before and after intra-nasal insulin exposure.
Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
|
Experimental: Insulin (MRI)
Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.
|
Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
|
Other: Time Control (Doppler)
Time control only
|
Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
Participants will be asked to repeatedly open and close their eyes.
With eyes open, participants will focus on a visual image.
This will be done before and after intra-nasal insulin exposure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of cerebral blood flow
Time Frame: Change from baseline at minute 15
|
Measured with trans-cranial Doppler ultrasound (cm/s) or arterial spin labeling (mL/100 g/min)
|
Change from baseline at minute 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of muscle sympathetic nerve activity (MSNA)
Time Frame: Change from baseline at minute 15
|
MSNA burst incidence (bursts/100 heart beats)
|
Change from baseline at minute 15
|
Amount of leg blood flow
Time Frame: Change from baseline at minute 15
|
Measured with Doppler ultrasound (mL/min)
|
Change from baseline at minute 15
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jacqueline K Limberg, Ph.D., University of Missouri-Columbia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2021
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
November 18, 2021
First Submitted That Met QC Criteria
December 8, 2021
First Posted (Actual)
December 10, 2021
Study Record Updates
Last Update Posted (Actual)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 21, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2057288
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Carbon dioxide breathing
-
SMG-SNU Boramae Medical CenterUnknownVentilation Perfusion Mismatch
-
Meshalkin Research Institute of Pathology of CirculationUnknownCarbon DioxideRussian Federation
-
Rutgers, The State University of New JerseyCompleted
-
Washington University School of MedicineRecruiting
-
Imperial College LondonUnknown
-
Imperial College LondonUnknownHeart Failure | Periodic BreathingUnited Kingdom
-
Imperial College LondonImperial College Healthcare NHS TrustUnknownSleep Apnea, CentralItaly, United Kingdom
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingBrain Diseases | Sickle Cell Disease | Anemia, Sickle Cell | Child, OnlyUnited States
-
GlaxoSmithKlineCompleted
-
Rikshospitalet University HospitalUniversity Hospital MuensterCompleted